Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $16.1 million.

  • Lipocine's Liabilities and Shareholders Equity fell 2234.55% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.7 million, marking a year-over-year decrease of 1574.96%. This contributed to the annual value of $22.5 million for FY2024, which is 213.28% down from last year.
  • According to the latest figures from Q3 2025, Lipocine's Liabilities and Shareholders Equity is $16.1 million, which was down 2234.55% from $18.6 million recorded in Q2 2025.
  • Lipocine's 5-year Liabilities and Shareholders Equity high stood at $52.5 million for Q4 2021, and its period low was $16.1 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $30.5 million (2023), whereas its average is $32.4 million.
  • Per our database at Business Quant, Lipocine's Liabilities and Shareholders Equity soared by 14093.33% in 2021 and then tumbled by 3873.39% in 2023.
  • Over the past 5 years, Lipocine's Liabilities and Shareholders Equity (Quarter) stood at $52.5 million in 2021, then decreased by 28.47% to $37.5 million in 2022, then tumbled by 38.73% to $23.0 million in 2023, then fell by 2.13% to $22.5 million in 2024, then dropped by 28.6% to $16.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $16.1 million in Q3 2025, compared to $18.6 million in Q2 2025 and $20.5 million in Q1 2025.